Cycling news
Remaining Tour de France riders given anti-doping blood tests
All remaining riders in the 2026 Tour de France underwent anti-doping blood testing as part of the ITA's Athlete Biological Passport programme.
Tour-wide controls
Every rider still in the 2026 Tour de France underwent an anti-doping blood test on Monday in Thonon-les-Bains, according to the International Testing Agency.
The important detail is the scope. This was not presented as a control focused on a named rider or team, but as a race-wide measure covering all riders who remained in the Tour. In a Grand Tour setting, that matters because anti-doping credibility is tied not only to individual cases, but to the consistency and reach of the testing programme across the field.
The ITA said the tests formed part of a comprehensive Athlete Biological Passport programme. For a data-driven audience, that framing is the key point: the story is less about a single headline outcome and more about the infrastructure around monitoring riders during the race. A full-peloton blood testing operation reinforces that the Tour's competitive picture is being assessed through formal biological controls, not just on-road performance.
Full details are at the linked CNA source.
Source: CNA